Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Emergent Biosolutions Inc. EBS

Healthcare — Drug Manufacturers Specialty & Generic

Emergent Biosolutions Inc. (EBS) Business Profile

Company Overview

Emergent BioSolutions Inc. (EBS) is a global life sciences company dedicated to providing solutions that address public health threats. Founded in 1998 and headquartered in Gaithersburg, Maryland, EBS has grown into a key player in the biopharmaceutical industry. The company was initially established to develop and manufacture vaccines and therapeutics for biological and chemical threats. Over the years, it has expanded its portfolio to include a wide range of medical countermeasures and commercial products.

The company is led by a team of experienced executives. As of 2023, Robert G. Kramer serves as the President and Chief Executive Officer, bringing decades of leadership experience in the pharmaceutical and biotechnology sectors. The leadership team also includes other key figures such as CFO Richard S. Lindahl and COO Paul Williams, who collectively drive the company’s strategic vision and operational excellence.

Core Business Segments

Emergent BioSolutions operates through several core business segments, each focusing on critical areas of public health and safety. These segments include:

1. Medical Countermeasures (MCM)

This segment is the backbone of EBS’s operations, focusing on products that address biological, chemical, radiological, and nuclear (CBRN) threats. Key products include:

  • BioThrax® (Anthrax Vaccine Adsorbed): The only FDA-licensed vaccine for the prevention of anthrax.
  • Raxibacumab: A monoclonal antibody for the treatment of inhalational anthrax.
  • Trobigard™: A combination auto-injector for emergency treatment of nerve agent poisoning.

2. Vaccines and Therapeutics

EBS develops and manufactures vaccines and therapeutics for infectious diseases. Notable products include:

  • ACAM2000®: A smallpox vaccine used for immunization against the disease.
  • Vaxchora®: The only FDA-approved vaccine for the prevention of cholera.
  • Narcan® (naloxone): A nasal spray used to reverse opioid overdoses.

3. Contract Development and Manufacturing (CDMO)

This segment provides contract services to pharmaceutical and biotechnology companies. Services include:

  • Development and manufacturing of biologics, vaccines, and therapeutics.
  • Fill/finish capabilities for injectable products.
  • Clinical trial material production.

4. Commercial Products

EBS also markets over-the-counter and prescription products that address public health needs. These include:

  • Travel health products: Vaccines and treatments for diseases like typhoid and cholera.
  • Opioid overdose solutions: Products like Narcan® to combat the opioid crisis.

Business Model

Emergent BioSolutions operates on a diversified business model that integrates product development, manufacturing, and commercialization. The company generates revenue through:

  • Government Contracts: A significant portion of EBS’s revenue comes from contracts with the U.S. government for the supply of medical countermeasures.
  • Product Sales: Revenue from the sale of vaccines, therapeutics, and over-the-counter products.
  • CDMO Services: Income from contract manufacturing and development services provided to third-party clients.

EBS’s vertically integrated approach allows it to control the entire lifecycle of its products, from research and development to manufacturing and distribution. This model ensures high-quality standards and cost efficiency.

Strategic Direction

Emergent BioSolutions is focused on expanding its portfolio and capabilities to address emerging public health threats. Key strategic initiatives include:

  • Pipeline Expansion: Investing in the development of new vaccines and therapeutics for infectious diseases and CBRN threats.
  • Global Reach: Expanding its presence in international markets to address global health challenges.
  • Sustainability Goals: Implementing environmentally sustainable practices in manufacturing and operations.
  • Innovation in CDMO Services: Enhancing its contract development and manufacturing capabilities to attract more clients.

Competitive Landscape

Emergent BioSolutions operates in a highly competitive environment. Key competitors include:

  • Pfizer Inc.: A global leader in vaccines and therapeutics.
  • Moderna, Inc.: Known for its mRNA-based vaccines.
  • Bavarian Nordic: A competitor in the smallpox and monkeypox vaccine market.
  • Catalent, Inc.: A major player in the CDMO space.

Despite the competition, EBS differentiates itself through its focus on medical countermeasures and its strong relationships with government agencies.

Risk Factors

Emergent BioSolutions faces several risks that could impact its operations and financial performance:

  • Market Dependence: A significant portion of revenue comes from government contracts, making the company vulnerable to changes in government spending.
  • Supply Chain Disruptions: Dependence on third-party suppliers for raw materials and components.
  • Regulatory Risks: Strict regulatory requirements for product approval and manufacturing.
  • Competition: Intense competition from larger pharmaceutical companies.
  • Public Perception: Negative publicity related to product recalls or manufacturing issues could harm the company’s reputation.

Recent Developments

In recent years, EBS has made significant strides in innovation and corporate strategy:

  • COVID-19 Response: Played a critical role in manufacturing COVID-19 vaccines for companies like Johnson & Johnson and AstraZeneca.
  • Narcan® Expansion: Increased production and distribution of Narcan® to combat the opioid crisis.
  • New Partnerships: Entered into collaborations with biotech firms to develop next-generation vaccines and therapeutics.
  • Facility Upgrades: Invested in expanding manufacturing facilities to meet growing demand.

Investment Considerations

Strengths:

  • Strong government relationships and contracts.
  • Diversified product portfolio addressing critical public health needs.
  • Expertise in vaccine and therapeutic development.
  • Growing CDMO business with high demand.

Risks:

  • Dependence on government contracts for revenue.
  • Regulatory and compliance challenges.
  • Competition from larger pharmaceutical companies.
  • Potential supply chain disruptions.

Conclusion

Emergent BioSolutions Inc. is a vital player in the biopharmaceutical industry, addressing critical public health threats through its diverse portfolio of products and services. With a strong focus on innovation, strategic partnerships, and global expansion, EBS is well-positioned for future growth. However, investors should carefully consider the risks associated with government dependence and regulatory challenges. Overall, EBS remains a compelling choice for those looking to invest in the life sciences sector.

© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us